clinical trial · NCT05075408
To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus
Galderma R&D·phase3·completed·n = 258
Chronic Kidney Disease Associated Moderate to Severe PruritusNemolizumabNemolizumabPlacebo
brief summary
The purpose of this study was to evaluate the efficacy of nemolizumab compared to placebo at reducing the intensity of pruritus after a 12-week treatment period in adult hemodialysis participants with moderate to severe pruritus.
started
Dec 29, 2021
primary completion
Jan 4, 2024
completion
Jan 4, 2024
last updated
Feb 20, 2025
official title
A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Nemolizumab in Subjects With Chronic Kidney Disease With Associated Moderate to Severe Pruritus
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol